EP0681484A1 - Reactants immunoreactifs utilisant des heterodimeres - Google Patents

Reactants immunoreactifs utilisant des heterodimeres

Info

Publication number
EP0681484A1
EP0681484A1 EP94907897A EP94907897A EP0681484A1 EP 0681484 A1 EP0681484 A1 EP 0681484A1 EP 94907897 A EP94907897 A EP 94907897A EP 94907897 A EP94907897 A EP 94907897A EP 0681484 A1 EP0681484 A1 EP 0681484A1
Authority
EP
European Patent Office
Prior art keywords
group
reagent
residue
mrp14
mrp8
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94907897A
Other languages
German (de)
English (en)
Inventor
Robert Allen Snow
Christopher Douglas Valiant Black
Clyde William Shearman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of EP0681484A1 publication Critical patent/EP0681484A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne un immunoréactant de ciblage non radioactif constitué d'un reste d'une moitié protéinique d'une molécule hétérodimère (H1), un groupe de liaison, et le reste d'un matériau immunoréactif associé à un agent d'apport radioactif constitué d'une seconde moitié protéinique d'une molécule hétérodimère (H2), un groupe de liaison, et un agent radioactif. Dans un autre aspect, cette invention concerne un immunoréactant de ciblage non radioactif constitué du reste d'une moitié protéinique d'une molécule hétérodimère (H2), un groupe de liaison et le reste d'un matériau immunoréactif associé à un agent d'apport radioactif constitué du reste d'une seconde moitié protéinique d'une molécule hétérodimère (H1), un groupe de liaison et un agent radioactif. Ces compositions comprennent des systèmes utiles pour la production d'une amplification d'apport de l'agent radioactif vers des sites tumoraux en thérapie et en imagerie diagnostiques de cancer.
EP94907897A 1993-01-28 1994-01-26 Reactants immunoreactifs utilisant des heterodimeres Withdrawn EP0681484A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1054493A 1993-01-28 1993-01-28
US10544 1993-01-28
PCT/US1994/000965 WO1994016741A1 (fr) 1993-01-28 1994-01-26 Reactants immunoreactifs utilisant des heterodimeres

Publications (1)

Publication Number Publication Date
EP0681484A1 true EP0681484A1 (fr) 1995-11-15

Family

ID=21746245

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94907897A Withdrawn EP0681484A1 (fr) 1993-01-28 1994-01-26 Reactants immunoreactifs utilisant des heterodimeres

Country Status (5)

Country Link
EP (1) EP0681484A1 (fr)
JP (1) JPH08509955A (fr)
AU (1) AU6128694A (fr)
CA (1) CA2154896A1 (fr)
WO (1) WO1994016741A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033627A2 (fr) * 1996-03-13 1997-09-18 Du Pont Pharmaceuticals Company Complexes ternaires radio-pharmaceutiques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9416741A1 *

Also Published As

Publication number Publication date
AU6128694A (en) 1994-08-15
CA2154896A1 (fr) 1994-08-04
WO1994016741A1 (fr) 1994-08-04
JPH08509955A (ja) 1996-10-22

Similar Documents

Publication Publication Date Title
EP0173629B1 (fr) Complexes d'ions métalliques conjugés avec des anticorps
US4741900A (en) Antibody-metal ion complexes
JP3095415B2 (ja) 免疫複合体の調製及び使用
US5807879A (en) Biotinidase-resistant biotinylated compound and methods of use thereof
US5171563A (en) Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
JPH0749377B2 (ja) 機能的特異性抗体
JPH01294700A (ja) 追跡標識接合体
JPH06501703A (ja) 治療用及び診断用撮像組成物及び方法において役立つ錯化剤及びターゲティング放射性免疫試薬
CA2150477A1 (fr) Ciblage sequentiel des sites tumoraux a l'aide de conjugues oligonucleotidiques d'anticorps et de conjugues oligonucleotidiques complementaires de radionucleides chelates
JPH06507918A (ja) ｉｎ　ｖｉｖｏ　結合対プレターゲティング
JP2792871B2 (ja) 金属イオンの除去方法およびそれに用いる溶液
EP0675737A1 (fr) Reactifs a reactivite immunologique utilisant la dihydrofolate reductase
CA2157902A1 (fr) Ciblage de tumeurs a l'aide de conjugues d'oligonucleotide l-enantiomeres d'immunoreactifs et de radionucleides chelates
CA2232601A1 (fr) Proteines recombinees ayant de multiples liaisons disulfure et conjugues a substitution thiol de ces proteines
RU2122431C1 (ru) Радиоактивный иммунореагент направленного действия, композиция для получения изображения злокачественного новообразования в организме, способ получения изображения и комплексообразующий агент
AU7244894A (en) Immunoreactive reagents employing monoamine oxidase
Mattes Pharmacokinetics of Antibodies and their Radiolabels
EP0681484A1 (fr) Reactants immunoreactifs utilisant des heterodimeres
EP4230637A1 (fr) Complexes radioactifs d'anticorps anti-her2 et produit radiopharmaceutique
Pollack et al. Hydrazino-type N 2 S 2 chelators
Frey Preparation, characterization and biological evaluation of cellobiose and dextran carriers of prosthetically labeled iodine-125 for use in radioimmunotherapy of tumors of glial origin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950627

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970801